Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Triana Baltzer, Gallen B ^a   Gubareva, Larisa V ^b   Nicholls, John M ^c   Pearce, Melissa B ^b   Mishin, Vasiliy P ^b   Belser, Jessica A ^b   Chen, Li Mei ^b   Chan, Renee W Y ^c   Chan, Michael C W ^c   Hedlund, Maria ^a   Larson, Jeffrey L ^a   Moss, Ronald B ^a   Katz, Jacqueline M ^b   Tumpey, Terrence M ^b   Fang, Fang ^a  

^a NexBio Inc   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DAS 181; FLUDASE; HYBRID PROTEIN; OSELTAMIVIR; UNCLASSIFIED DRUG; DAS181; SIALIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BRONCHUS MUCOSA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A H1N1; KIDNEY CELL; MOUSE; NONHUMAN; PROTECTION; RESPIRATORY SYSTEM; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS RESISTANCE; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; BRONCHUS; CHEMISTRY; DOG; FLUORESCENCE MICROSCOPY; KIDNEY; METABOLISM; METHODOLOGY;

AVES; INFECTIOUS FLACHERIE VIRUS; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIVIRAL AGENTS; BRONCHI; DOGS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; KIDNEY; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NEURAMINIDASE; OSELTAMIVIR; RECOMBINANT FUSION PROTEINS;

EID: 70450175741     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007788     Document Type: Article

References (52)

1. Cox NJ, Subbarao K (2000) Global epidemiology of influenza: past and present. Annu Rev Med 51: 407-421.
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
3. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009) Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med.
4. Belshe RB (2009) Implications of the Emergence of a Novel H1 Influenza Virus. N Engl J Med.
5. Miller MA, Viboud C, Balinska M, Simonsen L (2009) The Signature Features of Influenza Pandemics-Implications for Policy. N Engl J Med.
6. Shinde V, Bridges CB, Uyeki TM, Shu B, Balish A, et al. (2009) Triple-Reassortant Swine Influenza A (H1) in Humans in the United States, 2005-2009. N Engl J Med.
7. CDC (2009) Serum Cross-Reactive Antibody Response to a Novel Influenza A (H1N1) Virus After Vaccination with Seasonal Influenza Vaccine. Morbidity Mortality Weekly Report 58: 521-524.
8. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, et al. (2007) Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297: 1435-1442.
9. Hayden FG, Hay AJ (1992) Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 176: 119-130.
10. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
11. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, et al. (2003) Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother 9: 195-200.
12. Dharan NJ, Gubareva LV, Meyer JJ, Okomo-Adhiambo M, McClinton RC, et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 301: 1034-1041.
13. Moscona A (2005) Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353: 2633-2636.
14. Moscona A (2009) Global transmission of oseltamivir-resistant influenza. N Engl J Med 360: 953-956.
15. Hayden F (2009) Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 48 Suppl 1: S3-13.
16. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans. Science.
17. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, et al. (2006) Avian flu: influenza virus receptors in the human airway. Nature 440: 435-436.
18. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, et al. (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312: 404-410.
19. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, et al. (2006) Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 50: 1470-1479.
20. Nicholls JM, Aschenbrenner LM, Paulson JC, Campbell ER, Malakhov MP, et al. (2008) Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J Antimicrob Chemother 62: 426-428.
21. Ito T (2000) Interspecies transmission and receptor recognition of influenza A viruses. Microbiol Immunol 44: 423-430.
22. Belser JA, Lu X, Szretter KJ, Jin X, Aschenbrenner LM, et al. (2007) DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 196: 1493-1499.
23. Nicholls JM, Chan RWY, Chan MCW, Peiris M, Fang F (2009) DAS181 (Fludase(r)) Inhibits H5N1 Influenza virus Infection of Human Lung Tissues. Manuscript in review. Antimicrob Agents Chemother.
24. Triana-Baltzer GB, Nicholls JM, Chan RWY, Peiris JS, Chan MCW, et al. (2009) DAS181, A Sialidase Fusion Protein, Protects Human Airway Epithelium against Influenza Virus Infection: An In Vitro Pharmacodynamic Analysis. Manuscript in Preparation.
25. Gray TE, Guzman K, Davis CW, Abdullah LH, Nettesheim P (1996) Mucociliary differentiation of serially passaged normal human tracheobronchial epithelial cells. Am J Respir Cell Mol Biol 14: 104-112.
26. Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, et al. (2005) Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol 43: 4139-4146.
27. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD (2003) Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors 1. J Virol 77: 8418-8425.
28. Nettesheim P, Koo JS, Gray T (2000) Regulation of differentiation of the tracheobronchial epithelium. J Aerosol Med 13: 207-218.
29. Thompson CI, Barclay WS, Zambon MC, Pickles RJ (2006) Infection of human airway epithelium by human and avian strains of influenza a virus. J Virol 80: 8060-8068.
30. Thornton DJ, Gray T, Nettesheim P, Howard M, Koo JS, et al. (2000) Characterization of mucins from cultured normal human tracheobronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 278: L1118-L1128.
31. Johnson NP, Mueller J (2002) Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 76: 105-115.
32. Taubenberger JK, Morens DM (2006) 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 12: 15-22.
33. CDC (2009) Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 58: 433-435.
34. CDC (2009) "Flu View" Weekly U.S. Influenza Surveillance Report for Week 15 ending April 18 2009. http://www.cdc.gov/flu/weekly/ weeklyarchives2008-2009/weekly15.htm.
35. Cheng P, Leung T, Ho E, Leung P, Ng A, et al. (2009) Oseltamivir- and Adamantine-resistant influenza viruses A (H1N1). Emerg Infect Dis 15: 966-968.
36. Nelson MI, Viboud C, Simonsen L, Bennett RT, Griesemer SB, et al. (2008) Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918. PLoS Pathog 4: e1000012.
37. Simonsen L, Viboud C, Grenfell BT, Dushoff J, Jennings L, et al. (2007) The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 24: 1811-1820.
38. Stevens J, Blixt O, Glaser L, Taubenberger JK, Palese P, et al. (2006) Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 355: 1143-1155.
39. Stevens J, Blixt O, Chen LM, Donis RO, Paulson JC, et al. (2008) Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol 381: 1382-1394.
40. Ibricevic A, Pekosz A, Walter MJ, Newby C, Battaile JT, et al. (2006) Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol 80: 7469-7480.
41. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, et al. (2006) H5N1 Virus Attachment to Lower Respiratory Tract. Science 312: 399.
42. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG (2001) Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183: 523-531.
43. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
44. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
45. Gupta RK, Nguyen-Van-Tam JS (2006) Oseltamivir resistance in influenza A (H5N1) infection. N Engl J Med 354: 1423-1424.
46. Chen LM, Davis CT, Zhou H, Cox NJ, Donis RO (2008) Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog 4: e1000072.
47. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004) Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 101: 4620-4624.
48. Nicholls JM, Chan MC, Chan WY, Wong HK, Cheung CY, et al. (2007) Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract. Nat Med 13: 147-149.
49. Cowling BJ, Fung RO, Cheng CK, Fang VJ, Chan KH, et al. (2008) Preliminary findings of a randomized trial of non-pharmaceutical interventions to prevent influenza transmission in households. PLoS ONE 3: e2101.
50. Peiris JS, Tang WH, Chan KH, Khong PL, Guan Y, et al. (2003) Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 9: 628-633.
51. Chan KH, Peiris JS, Lim W, Nicholls JM, Chiu SS (2008) Comparison of nasopharyngeal flocked swabs and aspirates for rapid diagnosis of respiratory viruses in children. J Clin Virol 42: 65-69.
52. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, et al. (1999) A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73: 5903-5911.